Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 04, 2026
TickeronGET DAILY SIGNALS
electroCore (ECOR) Narrows Losses in Q3 as Margins Hit Record Highs

electroCore (ECOR) Narrows Losses in Q3 as Margins Hit Record Highs

Key Takeaways

  • electroCore reported third quarter 2026 net sales of approximately $9.7 million, up about 12% year over year, though below the roughly $10.9 million consensus revenue estimate.
  • Net loss narrowed to $1.3 million, or $0.13 per share, from $3.4 million, or $0.40 per share, a year earlier — beating the consensus estimate of a $0.26 per-share loss.
  • Adjusted EBITDA loss improved 67% year over year to $0.7 million, its lowest level on record, with gross margin expanding to 88.5%.
  • Full-year 2026 revenue guidance was revised to a range of $39 million to $42 million, while preliminary 2027 guidance calls for 30% to 40% growth and a first quarter of positive Adjusted EBITDA by the end of 2027.
  • Cash, cash equivalents, and marketable securities totaled approximately $7.5 million at September 30, 2026.

Why the Quarter Matters

electroCore is a commercial-stage bioelectronic medicine company whose prescription portfolio — led by gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell Fibromyalgia — is increasingly anchored in U.S. Department of Veterans Affairs (VA) sales. The third quarter report matters because it tests whether the company can convert a fast-expanding federal sales channel into structurally better profitability. Coming off back-to-back record revenue quarters, I was watching whether narrower losses and expanding gross margins would continue, and whether management's updated guidance would signal a credible, lower-cost path toward breakeven. The results carry added weight given the company's limited cash position and its stated goal of reaching positive Adjusted EBITDA without a new dilutive equity raise. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Breaking Down the Numbers

For the three months ended September 30, 2026, electroCore reported net sales of approximately $9.7 million, a roughly 12% increase from $8.7 million in the prior-year period. Growth was driven primarily by Quell Fibromyalgia and prescription gammaCore sales into the VA channel. Revenue came in below the approximately $10.9 million consensus estimate, while the company's loss per share of $0.13 was narrower than the $0.26 per-share loss analysts had expected.

Gross profit rose to $8.6 million, lifting gross margin to 88.5% from 86.0% a year earlier and 86.5% in the second quarter, reflecting favorable product mix. Operating expenses declined modestly to $10.1 million from $10.4 million a year ago. GAAP net loss was $1.3 million, or $0.13 per share, compared with $3.4 million, or $0.40 per share, in the third quarter of 2025. The quarter benefited from a non-recurring gain of about $0.4 million in other income related to an indemnification settlement.

Adjusted EBITDA loss narrowed to $0.7 million from $2.0 million a year earlier, an improvement of about 67%. Management revised full-year 2026 revenue guidance to $39 million to $42 million, from prior guidance of more than 30% growth, and introduced preliminary 2027 revenue growth guidance of 30% to 40%, with an expectation of achieving its first quarter of positive Adjusted EBITDA by the end of 2027.

Market Reaction and Investor Sentiment

Investor focus around this report centered less on the modest revenue miss and more on the sharp improvement in profitability and the updated pathway toward Adjusted EBITDA breakeven. The record-low loss from operations and 88.5% gross margin reinforced management's message that revenue growth is increasingly translating into bottom-line improvement. Still, sentiment carries a degree of caution: with roughly $7.5 million in cash and marketable securities at quarter-end, questions about funding runway and the pace of cash burn remain central to how the market interprets the results. From what I see, this balance between growth and cost control is worth tracking closely in the quarters ahead.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will likely focus on whether the company can deliver against its revised 2026 revenue range of $39 million to $42 million while continuing to narrow losses. The shift of VA prescription sales through the Lovell distribution agreement is expected to reduce transaction fees and free internal resources for new market development, a dynamic worth monitoring in the fourth quarter and into 2027.

Preliminary 2027 guidance of 30% to 40% revenue growth — and a first quarter of positive Adjusted EBITDA by the end of 2027 — sets a clear benchmark, but achieving it depends on sustained VA account expansion, faster new-representative productivity, and improved patient refill rates. Management has highlighted a national refill rate of 42% year to date, with a stated goal above 70%, making refill trends a key leading indicator.

Other factors to watch include potential label expansion for Quell for chemotherapy-induced peripheral neuropathy, which remains subject to FDA clearance, as well as the company's cash position and any future financing decisions. Progress on these fronts will shape whether electroCore can maintain its improved margin profile while scaling revenue across its federal and commercial channels. I’m watching this closely as the company works toward its profitability targets.

Using AI Tools for Deeper Analysis

In my view, tools like Tickeron’s AI Screener help cut through the noise when reviewing earnings like these. It lets me quickly compare ECOR against peers on fundamentals, patterns, and signals, which adds useful context to the reported results without replacing my own review of the numbers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ECOR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ECOR in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 12, 2026

ECOR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 37 cases where ECOR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +21.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where ECOR advanced for three days, in 240 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ECOR as a result. In 78 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for ECOR turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

The 10-day moving average for ECOR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ECOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for ECOR entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ECOR's P/B Ratio (-23.428) is slightly lower than the industry average of (4.142). P/E Ratio (-4.394) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.571) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ECOR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ECOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -6%. POAS experienced the highest price growth at 351%, while NPCE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 13 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of non-invasive neuromodulation therapies

Industry MedicalNursingServices

Industry
Medical Specialties
Address
200 Forge Way
Phone
+1 973 290-0097
Employees
83
Web
https://www.electrocore.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.